摘要
目的探讨乳腺癌原发灶与复发转移灶之间HER-2、COX-2和VEGF表达情况及其临床意义。方法应用免疫组化方法检测50例乳腺癌患者的原发灶和复发转移灶中HER-2、COX-2和VEGF的表达情况,并分析3个蛋白表达的相关性。结果 HER-2、COX-2、VEGF在原发灶和复发转移灶的阳性表达率分别为32%、76%、82%和24%、88%、38%,其中HER-2、COX-2在原发灶和复发转移灶之间差异均无统计学意义,而VEGF差异有统计学意义(P<0.05)。HER-2与COX-2表达在原发灶或复发转移灶中均无相关性(P>0.05),而COX-2与VEGF表达在原发灶中有相关性(P<0.05),但在复发转移灶中无相关性(P>0.05)。HER-2、COX-2、VEGF在原发灶和复发转移灶中发生变化的比例分别为12%、24%、60%。结论 HER-2、COX-2、VEGF在乳腺癌的发生发展中可能分别起到不同作用,在肿瘤进展的不同阶段其表达存在明显差异。
Objective To investigate expressions of HER-2,COX-2 and VEGF in primary and relapsed or metastatic focuses of breast cancer patients and their clinical significance. Methods Analysis was made on 50 breast cancer patients whose HER-2,COX-2 and VEGF expressions were determined in primary and relapsed or metastatic breast cancer tissue samples by immunohistochemistry. Results The positive expression rates of HER-2,COX-2 and VEGF were 32%,76%,82% in primary breast cancer,and 24%,88%,38% in relapsed or metastatic breast cancer（P〈0.05）.The positive expression rate of VEGF in relapsed or metastatic breast cancer was significantly higher than that in primary breast cancer（P〈0.05）.There was no correlation between HER-2 and COX-2 either in primary breast cancer or in relapsed or metastatic breast cancer（P〉0.05）.COX-2 was only related to VEGF in primary breast cancer.The proportion of HER-2,COX-2 and VEGF＇s changing between primary and relapsed or metastatic breast cancer was 12%,24% and 60% respectively. Conclusion HER-2,COX-2 and VEGF may act different effects in the development and progression of breast cancer,and their expressions are obviously different.
出处
《临床肿瘤学杂志》
CAS
2011年第11期984-987,共4页
Chinese Clinical Oncology
